These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 15330153

  • 1. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN.
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [Abstract] [Full Text] [Related]

  • 2. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [Abstract] [Full Text] [Related]

  • 3. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB, Isaacs JT.
    Cancer Res; 1997 Mar 15; 57(6):1054-7. PubMed ID: 9067270
    [Abstract] [Full Text] [Related]

  • 4. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 5. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 6. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW.
    Cancer Res; 1992 Mar 15; 52(6):1598-605. PubMed ID: 1371718
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 8. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA.
    Cancer Res; 2009 Jun 01; 69(11):4708-15. PubMed ID: 19487287
    [Abstract] [Full Text] [Related]

  • 9. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y, Mizokami A, Miwa S, Koshida K, Namiki M.
    Int J Urol; 2007 Mar 01; 14(3):233-9. PubMed ID: 17430262
    [Abstract] [Full Text] [Related]

  • 10. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 11. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
    Tesan T, Gustavsson H, Welén K, Damber JE.
    BJU Int; 2008 Sep 01; 102(8):1034-9. PubMed ID: 18489523
    [Abstract] [Full Text] [Related]

  • 12. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
    Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R.
    Cancer Epidemiol Biomarkers Prev; 2003 Sep 01; 12(9):933-9. PubMed ID: 14504208
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME, Goddard L, Smith C, Nicholson RI.
    Prostate; 2004 Jan 01; 58(1):13-22. PubMed ID: 14673948
    [Abstract] [Full Text] [Related]

  • 14. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
    Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD.
    Prog Urol; 1996 Jun 01; 6(3):375-85. PubMed ID: 8763692
    [Abstract] [Full Text] [Related]

  • 15. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
    Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clézardin P, Cabon F.
    Cancer Res; 2005 Jan 01; 65(1):300-8. PubMed ID: 15665307
    [Abstract] [Full Text] [Related]

  • 16. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ.
    Cancer Res; 2000 Feb 01; 60(3):741-8. PubMed ID: 10676662
    [Abstract] [Full Text] [Related]

  • 17. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 18. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
    Lee SC, Chan WK, Lee TW, Lam WH, Wang X, Chan TH, Wong YC.
    Nutr Cancer; 2008 Jun 01; 60(4):483-91. PubMed ID: 18584482
    [Abstract] [Full Text] [Related]

  • 19. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.
    Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K.
    Clin Cancer Res; 2006 May 15; 12(10):3003-9. PubMed ID: 16707595
    [Abstract] [Full Text] [Related]

  • 20. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 15; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.